IRIS
ARMENI, PATRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.006
NA - Nord America 7.511
AS - Asia 3.315
SA - Sud America 382
Continente sconosciuto - Info sul continente non disponibili 275
AF - Africa 97
OC - Oceania 24
Totale 21.610
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.176
IT - Italia 3.754
RU - Federazione Russa 1.914
CN - Cina 1.024
FI - Finlandia 1.023
GB - Regno Unito 870
SG - Singapore 832
IE - Irlanda 726
UA - Ucraina 349
DE - Germania 347
VN - Vietnam 345
BR - Brasile 299
FR - Francia 291
CA - Canada 243
HK - Hong Kong 227
SE - Svezia 173
TR - Turchia 161
NL - Olanda 155
IN - India 141
KR - Corea 127
BD - Bangladesh 126
CZ - Repubblica Ceca 61
PL - Polonia 56
ES - Italia 51
ID - Indonesia 51
BG - Bulgaria 50
ZA - Sudafrica 50
BE - Belgio 45
IL - Israele 45
MX - Messico 45
IQ - Iraq 32
JP - Giappone 32
AR - Argentina 30
AT - Austria 28
CH - Svizzera 25
PK - Pakistan 22
AU - Australia 19
CO - Colombia 19
RO - Romania 19
AE - Emirati Arabi Uniti 16
IR - Iran 16
DK - Danimarca 12
PH - Filippine 12
EC - Ecuador 11
MA - Marocco 11
MY - Malesia 11
TH - Thailandia 11
UZ - Uzbekistan 11
CL - Cile 10
PT - Portogallo 9
TW - Taiwan 9
EU - Europa 8
GR - Grecia 8
HN - Honduras 8
JO - Giordania 8
JM - Giamaica 7
PA - Panama 7
SA - Arabia Saudita 7
AM - Armenia 6
AZ - Azerbaigian 6
CR - Costa Rica 6
GE - Georgia 6
KE - Kenya 6
LT - Lituania 6
LV - Lettonia 6
EG - Egitto 5
GT - Guatemala 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
TN - Tunisia 5
VE - Venezuela 5
KG - Kirghizistan 4
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
SI - Slovenia 4
CG - Congo 3
DZ - Algeria 3
EE - Estonia 3
NO - Norvegia 3
PE - Perù 3
PS - Palestinian Territory 3
SN - Senegal 3
SV - El Salvador 3
AL - Albania 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
BZ - Belize 2
CW - ???statistics.table.value.countryCode.CW??? 2
LB - Libano 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MD - Moldavia 2
NG - Nigeria 2
OM - Oman 2
PR - Porto Rico 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
UG - Uganda 2
A1 - Anonimo 1
Totale 21.320
Salva come PNG Salva come JPEG
Città #
Ashburn 972
San Jose 963
Helsinki 957
Milan 808
Dublin 718
Southend 532
Chandler 484
Singapore 436
Dallas 379
Moscow 356
Council Bluffs 354
Hefei 353
Rome 305
Jacksonville 277
Beijing 235
Ann Arbor 234
Hong Kong 222
New York 182
Toronto 157
The Dalles 156
Los Angeles 152
Dearborn 128
Seoul 125
Houston 110
Dong Ket 104
Edison 93
Ho Chi Minh City 91
Columbus 87
Boston 81
Wilmington 80
Naples 78
Lauterbourg 75
Modena 70
Boardman 65
Bologna 65
Lawrence 64
Chicago 61
Munich 60
Izmir 56
Turin 55
Bari 53
Buffalo 50
Hanoi 48
Florence 47
Santa Clara 47
Johannesburg 46
Frankfurt am Main 43
Brussels 41
Jakarta 41
Redwood City 41
São Paulo 41
Warsaw 41
Catania 40
Tel Aviv 40
Redmond 39
Phoenix 38
Seattle 38
Orem 37
Montreal 35
Genoa 34
London 34
Mountain View 34
Woodbridge 33
Assago 32
Chennai 32
Amsterdam 30
Brooklyn 30
Cagliari 30
Casorate Primo 30
Tokyo 28
Falkenstein 23
Palermo 22
Atlanta 21
Secaucus 21
Brescia 20
Denver 20
Lappeenranta 19
Mexico City 19
Brno 18
Duncan 18
Kunming 18
Miano 18
Nanjing 18
Verona 18
Washington 17
Poplar 16
Busto Arsizio 15
Paris 15
Parma 15
Pescara 15
Pisa 15
Stockholm 15
Rio de Janeiro 14
Baghdad 13
Palombara Sabina 13
Torino 13
Venice 13
Bonndorf 12
Kocaeli 12
Monza 12
Totale 12.431
Salva come PNG Salva come JPEG
Nome #
Digitalizzazione nelle tecnologie per la salute: impatto sui livelli di governo del SSN 743
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 469
The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study 467
La copertura vaccinale nelle regioni italiane. Un’analisi dell’eterogeneità 448
Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci 446
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 405
Cost-benefit analysis in health care: the case of bariatric surgery compared with diet 388
Report n. 42 OSFAR (Osservatorio Farmaci) 383
La spesa sanitaria: composizione ed evoluzione 375
I dispositivi medici in Italia: un settore, tanti mercati 355
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 336
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 332
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service 328
Market access management by pharmaceutical companies in a complex environment: the Italian case study 324
La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane 321
Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento 316
Il confronto dei sistemi sanitari in una prospettiva internazionale 307
L'acquisto di farmaci in Italia: l'effetto di approcci selettivi 307
Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis 303
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 290
The future of Funds for Innovative Medicines: results from a Delphi Study 287
Diffusion without evidence: a study on high-risk medical devices 280
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy 279
La spesa sanitaria: composizione ed evoluzione 277
Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review 270
A value-based revolution in health care: perspectives, challenges, and emerging approaches to defining and measuring the value of health care technologies 270
Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation 270
Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa 269
Collecting physicians' preferences on medical devices: are we doing it right? Evidence from Italian orthopedists using 2 different stated preference methods 266
Digital Twins in healthcare: is it the beginning of a new era of evidence-based medicine? A critical review 265
PHP3 the simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 259
Programma Nazionale di HTA per dispositivi medici: prove tecniche di implementazione 259
L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni 255
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) 251
Il confronto dei sistemi sanitari in una prospettiva internazionale 247
La spesa sanitaria: composizione ed evoluzione 247
Il confronto dei sistemi sanitari in una prospettiva internazionale 245
I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia 239
Politiche del farmaco: approfondimento sul Value Framework per i farmaci 238
Cost-effectiveness and net monetary benefit of Olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service 237
La spesa sanitaria: composizione ed evoluzione 235
The impact of HTA and procurement practices on the selection and prices of medical devices 234
A meta-analysis of MitraClip combined with medical therapy versus medical therapy alone for treatment of mitral regurgitation in heart failure patients 232
Cost-effectiveness analysis of HRD testing for previously treated patients with advanced ovarian cancer in Italy 230
The invisible costs of obstructive sleep apnea (OSA): systematic review and cost-of-illness analysis 230
Implementation of value-based pricing for medicines 223
L'attività sperimentale sui dispositivi medici 215
Il confronto dei sistemi sanitari in una prospettiva internazionale 214
The impact of generic reference pricing in Italy, a decade on 212
Il confronto dei sistemi sanitari in una prospettiva internazionale 205
When peers count: the effects on integrated type II diabetes care of communication within general practitioner-only subgroups in interprofessional primary care teams 203
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention 202
La spesa sanitaria: composizione ed evoluzione 199
Economic impact of a more extensive use of FENO testing on the Italian population with asthma 197
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case 197
The impact of generic reference pricing in Italy, a decade on 197
Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients 194
Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey 194
The value of hearing aids for the Italian NHS: a cost-utility analysis 182
L’evoluzione del finanziamento dei farmaci in Italia 181
La spesa sanitaria: composizione ed evoluzione 181
The social burden and quality of life of patients with haemophilia in Italy 179
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 178
Multi-professional primary care units: what affects the clinical performance of Italian general practitioners? 176
Social/economic costs and quality of life in patients with haemophilia in Europe 174
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 172
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 170
What type of clinical evidence is needed to assess medical devices? 170
La spesa sanitaria: composizione ed evoluzione 169
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 165
Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe 163
The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study 162
Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy 157
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe 153
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment 151
Exploring the potential of digital therapeutics: an assessment of progress and promise 143
Social economic costs, health-related quality of life and disability in patients with Cri Du Chat syndrome 142
La spesa sanitaria: composizione ed evoluzione 139
Variations in non-prescription drug consumption and expenditure: determinants and policy implications 134
La spesa sanitaria: composizione ed evoluzione 129
Use of resource modeling to quantify the organizational impact of subcutaneous formulations for the treatment of oncologic patients: the case of daratumumab in multiple myeloma 128
La spesa sanitaria: composizione ed evoluzione 127
Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries 124
La spesa sanitaria: composizione ed evoluzione 120
The economic burden of anesthetic-related adverse events: a systematic review and empirical analysis 118
The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States 118
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes 115
Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure 112
Reflections on the importance of cost of illness analysis in rare diseases: a proposal 100
Individual and team performanc: issues around the role of attributes and relationships among peers 92
The relationship between trust and compliance in the Italian NHS: Results of the People's Voice Survey 79
Implementing the EU HTA regulation and joint clinical assessment: a multi-stakeholder perspective from Italy 50
Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy 46
Promoting healthy aging in a digital world: leveraging technology for enhanced elderly care and wellbeing 45
Totale 21.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.957
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.957
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022651 0 0 0 41 66 12 31 174 41 47 105 134
2022/20232.347 119 127 58 176 153 189 63 101 977 94 165 125
2023/20241.807 104 97 123 89 167 177 105 279 99 136 211 220
2024/20252.490 138 36 170 123 209 157 162 165 571 286 303 170
2025/20268.588 559 647 292 573 605 336 906 837 2.269 896 498 170
2026/20271.729 285 456 493 495 0 0 0 0 0 0 0 0
Totale 21.610